Universität zu Köln

Journal Article

Abruzzo, Lynne, Herling, Carmen, Coombes, Kevin, Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary, Majewski, Tadeusz, Bondaruk, Jolanta, Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan, Oakes, Christopher, Ferrajoli, Alessandra and Keating, Michael (2020). Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL. Leuk. Lymphoma, 61. S. 7 - 9. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Agathangelidis, Andreas ORCID: 0000-0002-8467-7945, Chatzidimitriou, Anastasia, Gemenetzi, Katerina, Giudicelli, Veronique, Karypidou, Maria, Plevova, Karla ORCID: 0000-0002-6148-8877, Davis, Zadie, Yan, Xiao-Jie, Jeromin, Sabine, Schneider, Christof, Pedersen, Lone Bredo, Tschumper, Renee C., Sutton, Lesley-Ann, Baliakas, Panagiotis, Scarfo, Lydia, van Gastel, Ellen J., Armand, Marine, Tausch, Eugen, Biderman, Bella, Baer, Constance, Bagnara, Davide, Navarro, Alba, de Septenville, Anne Langlois, Guido, Valentina, Mitterbauer-Hohendanner, Gerlinde, Dimovski, Aleksandar, Brieghel, Christian ORCID: 0000-0002-1816-8106, Lawless, Sarah, Meggendorfer, Manja, Brazdilova, Kamila, Ritgen, Matthias, Facco, Monica, Tresoldi, Cristina, Visentin, Andrea ORCID: 0000-0003-0271-7200, Patriarca, Andrea ORCID: 0000-0003-4415-2906, Catherwood, Mark, Bonello, Lisa, Sudarikov, Andrey ORCID: 0000-0001-9463-9187, Vanura, Katrina, Roumelioti, Maria, Francova, Hana Skuhrova, Moysiadis, Theodoros ORCID: 0000-0003-1673-196X, Veronese, Silvio, Giannopoulos, Krzysztof, Mansouri, Larry, Karan-Djurasevic, Teodora, Sandaltzopoulos, Raphael, Bodor, Csaba, Fais, Franco ORCID: 0000-0002-6643-7083, Kater, Arnon, Panovska, Irina, Rossi, Davide, Alshemmari, Salem ORCID: 0000-0002-5597-5839, Panagiotidis, Panagiotis, Costeas, Paul, Espinet, Blanca ORCID: 0000-0002-4294-8145, Antic, Darko, Foroni, Letizia, Montillo, Marco, Trentin, Livio, Stavroyianni, Niki, Gaidano, Gianluca ORCID: 0000-0002-4681-0151, di Celle, Paola Francia, Niemann, Carsten ORCID: 0000-0001-9880-5242, Campo, Elias, Anagnostopoulos, Achilles, Pott, Christiane, Fischer, Kirsten, Hallek, Michael, Oscier, David, Stilgenbauer, Stephan, Haferlach, Claudia, Jelinek, Diane, Chiorazzi, Nicholas, Pospisilova, Sarka, Lefranc, Marie-Paule, Kossida, Sofia, Langerak, Anton W., Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo and Stamatopoulos, Kostas ORCID: 0000-0001-8529-640X (2021). Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 137 (10). S. 1365 - 1377. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Herling, Carmen D., Hoechstetter, Manuela, Fink, Anna-Maria, von Tresckow, Julia, Langerbeins, Petra, Cramer, Paula, Stilgenbauer, Stephan, Wendtner, Clemens M., Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2018). Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br. J. Haematol., 183 (5). S. 727 - 736. HOBOKEN: WILEY. ISSN 1365-2141

Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). Am. J. Hematol., 94 (9). S. 1002 - 1007. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman and Fischer, Kirsten (2021). TP53 mutations in CLL: does frequency matter? Blood, 138 (25). S. 2600 - 2602. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2016). Targeted Therapy of CLL. Oncol. Res. Treat., 39 (12). S. 768 - 777. BASEL: KARGER. ISSN 2296-5262

Al-Sawaf, Othman, Fischer, Kirsten, Engelke, Anja, Pflug, Natali, Hallek, Michael and Goede, Valentin (2017). Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des. Dev. Ther., 11. S. 295 - 305. ALBANY: DOVE MEDICAL PRESS LTD. ISSN 1177-8881

Al-Sawaf, Othman, Fischer, Kirsten, Herling, Carmen D., Ritgen, Matthias, Boettcher, Sebastian, Bahlo, Jasmin, Elter, Thomas, Stilgenbauer, Stephan, Eichhorst, Barbara F., Busch, Raymonde, Elberskirch, Ute, Abenhardt, Wolfgang, Kneba, Michael, Hallek, Michael and Wendtner, Clemens-Martin (2017). Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur. J. Haematol., 98 (3). S. 254 - 263. HOBOKEN: WILEY. ISSN 1600-0609

Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Gentile, Brittany ORCID: 0000-0002-6302-5593, Devine, Jacob, Zhang, Can, Sail, Kavita, Tandon, Maneesh, Fink, Anna-Maria, Kutsch, Nadine, Wendtner, Clemens-Martin, Eichhorst, Barbara, Hallek, Michael and Fischer, Kirsten (2021). Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am. J. Hematol., 96 (9). S. 1112 - 1120. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Lilienweiss, Esther, Bahlo, Jasmin, Robrecht, Sandra, Fink, Anna-Maria, Patz, Michaela, Tandon, Maneesh, Jiang, Yanwen, Schary, William, Ritgen, Matthias, Tausch, Eugen, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael and Kreuzer, Karl-Anton (2020). High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 135 (11). S. 866 - 871. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna Maria, Cramer, Paula, Maurer, Christian, Bergmann, Manuela A., Dreyling, Martin H., Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Dohner, Hartmut, Kiehl, Michael G., Jager, Ulrich, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara F. and Hopfinger, Georg (2016). Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Cramer, Paula, Maurer, Christian, Bergmann, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Jaeger, Ulrich, Wendtner, Clemens, Fischer, Kirsten, Goede, Valentin, Hallek, Michael, Eichhorst, Barbara, Hopfinger, Georg, Doehner, Hartmut and Kiehl, Michael (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG). Leuk. Lymphoma, 58. S. 62 - 64. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Cramer, Paula, von Tresckow, Julia, Lange, Elisabeth, Kiehl, Michael, Dreyling, Martin, Rittgen, Matthias, Duerig, Jan, Fischer, Kirsten, Stilgenbauer, Stephan, Wendtner, Clemens, Goede, Valentin, Hallek, Michael and Eichhorst, Barbara (2020). Richter transformation in CLL: a meta-analysis of GCLLSG trials. Leuk. Lymphoma, 61. S. 98 - 101. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Seymour, John F., Kater, Arnon P. and Fischer, Kirsten (2021). Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy? Hematol. Oncol. Clin. North Am., 35 (4). S. 775 - 792. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1558-1977

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna Maria, Robrecht, Sandra, Tausch, Eugen, Schary, William L., Ritgen, Matthias, Wendtner, Clemens Martin, Kreuzer, Karl A., Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael J. and Fischer, Kirsten (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Bahlo, Jasmin, Pflug, Natali, Elter, Thomas, Bauer, Kathrin, Eichhorst, Barbara, Bergmann, Manuela, Busch, Raymonde, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten and Hallek, Michael (2011). Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials. Blood, 118 (21). S. 1219 - 1221. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Beckmann, Laura, Berg, Valeska, Dickhut, Clarissa, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Huelsemann, Malte, Loroch, Stefan, Merkel, Olaf, Fischer, Kirsten, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Sickmann, Albert ORCID: 0000-0002-2388-5265, Hallek, Michael, Zahedi, Rene and Frenzel, Lukas P. (2018). Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Beckmann, Laura ORCID: 0000-0001-5207-8991, Berg, Valeska, Dickhut, Clarissa, Sun, Clare ORCID: 0000-0001-8498-4729, Merkel, Olaf, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Robrecht, Sandra, Seifert, Marc, Guerreiro, Alexandra da Palma, Claasen, Julia, Loroch, Stefan, Oliverio, Matteo, Underbayev, Chingiz, Vaughn, Lauren, Thomalla, Daniel, Huelsemann, Malte F., Tausch, Eugen, Fischer, Kirsten, Fink, Anna Maria ORCID: 0000-0002-7669-7890, Eichhorst, Barbara, Sickmann, Albert ORCID: 0000-0002-2388-5265, Wendtner, Clemens M., Stilgenbauer, Stephan, Hallek, Michael, Wiestner, Adrian, Zahedi, Rene P. and Frenzel, Lukas P. (2021). MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood, 138 (7). S. 544 - 557. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Braun, Andrejs ORCID: 0000-0003-0925-5598, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars ORCID: 0000-0002-5890-5510, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz ORCID: 0000-0002-3411-6357, Schneider, Christof, Gribben, John, Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J., Doehner, Hartmut, Stilgenbauer, Stephan and Mertens, Daniel (2021). Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat. Commun., 12 (1). BERLIN: NATURE PORTFOLIO. ISSN 2041-1723

Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Krzykalla, Julia, Holzmann, Karlheinz, Gerhardinger, Andreas, Jebaraj, Billy Michael Chelliah, Bahlo, Jasmin, Humphrey, Kathryn, Tausch, Eugen, Robrecht, Sandra, Mertens, Daniel ORCID: 0000-0003-0227-7188, Schneider, Christof, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455, Doehner, Hartmut, Benner, Axel and Stilgenbauer, Stephan (2022). Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. Haematologica, 107 (3). S. 615 - 625. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Bloehdorn, Johannes, Krzykalla, Julia, Jebaraj, Billy Michael Chelliah, Holzmann, Karlheinz, Bahlo, Jasmin, Robrecht, Sandra, Humphrey, Kathryn, Wenger, Michael, Tausch, Eugen, Schneider, Christof, Bullinger, Lars, Fischer, Kirsten, Hallek, Michael, Mertens, Daniel, Benner, Axel, Doehner, Hartmut and Stilgenbauer, Stephan (2018). MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Boeitcher, Sebastian, Ritgen, Matthias, Fischer, Kirsten, Stilgenbauer, Stephan, Busch, Raymonde, Fingerle-Rowson, Gunter R., Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Wenger, Michael K., Mendila, Myriam, Wendtner, Clemens, Eichhorst, Barbara, Doehner, Hartmut, Hallek, Michael and Kneba, Michael (2011). Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups-Results From the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 775 - 776. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Brown, Jennifer, Tiao, Grace, Kasar, Siddha, Improgo, Ma Reina, Poh, Weijie, Kamburov, Atanas, Landau, Dan-Avi, Tausch, Eugen, Taylor-Weiner, Amaro, Cibulskis, Carrie, Bahl, Samira, Fernandes, Stacey, Hoang, Kevin, Kim, Haesook T., Bahlo, Jasmin, Rheinbay, Esther, Robrecht, Sandra, Fischer, Kirsten, Hallek, Michael, Gabriel, Stacey, Lander, Eric S., Stilgenbauer, Stephan, Wu, Catherine J., Kiezun, Adam and Getz, Gad (2017). Germline rare variant association analysis in chronic lymphocytic leukemia. Leuk. Lymphoma, 58. S. 126 - 128. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, Bahlo, Jasmin, Eichhorst, Barbara, Fischer, Kirsten and Hallek, Michael (2014). Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual. Leuk. Res., 38 (3). S. 284 - 286. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835

Cramer, Paula, Fink, Anna-Maria, Busch, Raymonde, Eichhorst, Barbara, Wendtner, Clemens-Martin, Pflug, Natali, Schubert, Friederike, Doehner, Hartmut, Rieger, Michael, Kneba, Michael, Mayer, Jiri, Hallek, Michael and Fischer, Kirsten (2011). Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 1235 - 1236. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Cramer, Paula ORCID: 0000-0003-4046-9922, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial. Lancet Haematol., 9 (10). S. E745 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Cramer, Paula, Isfort, Susanne, Bahlo, Jasmin, Stilgenbauer, Stephan, Doehner, Hartmut, Bergmann, Manuela, Stauch, Martina, Kneba, Michael, Lange, Elisabeth, Langerbeins, Petra, Pflug, Natali, Kovacs, Gabor, Goede, Valentin, Fink, Anna-Maria, Elter, Thomas, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael and Eichhorst, Barbara (2015). Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica, 100 (11). S. 1451 - 1460. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cramer, Paula, Langerbeins, Petra, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2016). Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all? Leuk. Lymphoma, 57 (5). S. 987 - 991. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Furstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria ORCID: 0000-0002-7669-7890, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2021). Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 138 (19). S. 1805 - 1817. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2018). CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol., 14 (6). S. 499 - 514. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Wesselmann, Johanna Sofie, Annolleck, Tanja, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2015). CLL2-BIG, -BAG, -BCG and -BIO: a series of four phase-II trials evaluating a sequential tailored and targeted regimen aiming for total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Leuk. Lymphoma, 56. S. 143 - 145. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Rittgen, Matthias, Kneba, Michael, Wendtner, Clemens, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2017). Sequential treatment with bendamustine, followed by obinutuzumab (GA101) and venetoclax (ABT-199) in patients with chronic lymphocytic leukemia (CLL): results of the CLL2-BAG phase-II-trial of the German CLL study group (GCLLSG). Leuk. Lymphoma, 58. S. 149 - 151. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Balke-Want, Hyatt, Al-Sawaf, Othman, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Fischer, Kirsten, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara F. and Hallek, Michael (2016). Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Al-Sawaf, Othman, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Tausch, Eugen, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol., 19 (9). S. 1215 - 1229. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Fuerstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2018). Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica, 106 (2). S. 543 - 555. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Dimier, Natalie, Delmar, Paul, Ward, Carol, Morariu-Zamfir, Rodica, Fingerle-Rowson, Guenter, Bahlo, Jasmin, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Langerak, Anton W., Kneba, Michael and Hallek, Michael (2018). A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 131 (9). S. 955 - 963. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Dimier, Natalie, Delmar, Paul, Ward, Carol, Morariu-Zamfir, Rodica, Fingerle-Rowson, Gunter, Bahlo, Jasmin, Fischer, Kirsten, Eichhorst, Barbara F., Goede, Valentin, van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Langerak, Anton W., Kneba, Michael and Hallek, Michael (2015). A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Edelmann, Jennifer, Holzmann, Karlheinz, Tausch, Eugen, Saunderson, Emily A., Jebaraj, Billy M. C., Steinbrecher, Daniela, Dolnik, Anna, Blaette, Tamara J., Landau, Dan A., Saub, Jenny, Estenfelder, Sven, Ibach, Stefan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain ORCID: 0000-0002-1430-2574, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Goede, Valentin, Bullinger, Lars, Wu, Catherine J., Mertens, Daniel ORCID: 0000-0003-0227-7188, Ficz, Gabriella, Gribben, John G., Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2020). Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica, 105 (5). S. 1379 - 1391. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Edelmann, Jennifer, Tausch, Eugen, Bloehdorn, Johannes, Zenz, Thorsten, Fischer, Kirsten, Bahlo, Jasmin, Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2014). High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response? Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Bahlo, Jasmin, Fink, Anna Maria, Pfreundschuh, Michael, Hebart, Holger, Maschmeyer, Georg, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Westermann, Anne, Zey, Aline, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Doehner, Hartmut, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Fink, Anna Maria, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg R. A., Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Fink, Anna-Maria, Bahlo, Jasmin, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael, Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek ORCID: 0000-0002-6952-6073, Fischer, Kirsten, Doehner, Harmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2016). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol., 17 (7). S. 928 - 943. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Eichhorst, Barbara F., Bahlo, Jasmin, Maurer, Christian, Lange, Elisabeth, Koppler, Hubert, Kiehl, Michael G., Sokler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Kochling, Georg, Ploger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Dohner, Hartmut, Kneba, Michael, Wendtner, Clemens, Klapper, Wolfram, Kreuzer, Karl-Anton, Bottcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria and Hallek, Michael (2016). Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Estenfelder, Sven, Tausch, Eugen, Robrecht, Sandra, Bahlo, Jasmin, Goede, Valentin, Ritgen, Matthias, van Dongen, Jacques J. M., Langerak, Anton W., Fingerle-Rowson, Gunter, Kneba, Michael, Fischer, Kirsten, Hallek, Michael, Dohner, Hartmut and Stilgenbauer, Stephan (2016). Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2011). Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 446 - 448. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo ORCID: 0000-0003-3750-7342, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Dohner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2017). Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol., 4 (10). S. E475 - 12. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Fink, Anna Maria, Bahlo, Jasmin, Sandra, Robrecht, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Dohner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fink, Anna-Maria, Robrecht, Sandra, Bahlo, Jasmin, Fuerstenau, Moritz, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Rittgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2020). Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy. Leuk. Lymphoma, 61. S. 272 - 274. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fischer, Kirsten and Al-Sawaf, Othman (2021). Acalabrutinib monotherapy in patients with Richter transformation. Lancet Haematol., 8 (12). S. E868 - 3. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin H., Opat, Stephen, Owen, Carolyn J., Lopez, Javier, Humphrey, Kathryn, Humerickhouse, Rod A., Tausch, Eugen, Eichhorst, Barbara, Wendtner, Clemens-M., Langerak, Anton W., van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Stilgenbauer, Stephan, Goede, Valentin, Mobasher, Mehrdad and Hallek, Michael (2016). Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Humphrey, Kathryn, Humerickhouse, Rod, Tausch, Eugen, Frenzel, Lukas, Eichhorst, Barbara, Wendtner, Clemens-M., Stilgenbauer, Stephan, Langerak, Anton W., van Dongen, Jacque J. M., Boettcher, Sebastian, Ritgen, Matthias, Goede, Valentin, Mobasher, Mehrdad and Hallek, Michael (2017). Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 129 (19). S. 2702 - 2706. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Al-Sawaf, Othman and Hallek, Michael (2020). Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematol.-Am. Soc. Hematol. Educ. Program (1). S. 357 - 363. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna Maria, Goede, Valentin, Herling, Carmen Diana, Cramer, Paula, Langerbeins, Petra, von Tresckow, Julia, Engelke, Anja, Maurer, Christian, Kovacs, Gabor, Herling, Marco, Tausch, Eugen, Kreuzer, Karl-Anton, Eichhorst, Barbara, Boettcher, Sebastian, Seymour, John F., Ghia, Paolo ORCID: 0000-0003-3750-7342, Marlton, Paula, Kneba, Michael, Wendtner, Clemens-Martin, Doehner, Hartmut, Stilgenbauer, Stephan and Hallek, Michael (2016). Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 127 (2). S. 208 - 216. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna-Maria, Busch, Raymonde, Boettcher, Sebastian, Mayer, Jiri, Dreger, Peter, Maurer, Christian, Engelke, Anja, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Wendtner, Clemens-Martin, Stilgenbauer, Stephan and Hallek, Michael (2012). Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Boettcher, Sebastian, Bahlo, Jasmin, Schubert, Joeerg, Pflueger, Karl H., Schott, Silke, Goede, Valentin, Isfort, Susanne, von Tresckow, Julia, Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Kreuzer, Karl-Anton, Staib, Peter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Stilgenbauer, Stephan and Wendtner, Clemens-Martin (2012). Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol., 30 (26). S. 3209 - 3217. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Stilgenbauer, Stephan, Bahlo, Jasmin, Schweighofer, Carmen D., Boettcher, Sebastian, Staib, Peter, Kiehl, Michael, Eckart, Michael J., Kranz, Gabriele, Goede, Valentin, Elter, Thomas, Buehler, Andreas, Winkler, Dirk, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael and Wendtner, Clemens-Martin (2011). Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol., 29 (26). S. 3559 - 3567. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fischer, Kirsten, Fink, Anna-Maria, Bishop, Helen, Dixon, Mark, Bahlo, Jasmin, Chol, Michael Y., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Sr., Kutsch, Nadine, Tausch, Eugen, Ritgen, Matthias, Humerickhouse, Rod A., Humphrey, Kathryn, Wenger, Michael K., Goede, Valentin, Eichhorst, Barbara, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Kipps, Thomas J. and Hallek, Michael (2015). Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten and Hallek, Michael (2017). Optimizing frontline therapy of CLL based on clinical and biological factors. Hematol.-Am. Soc. Hematol. Educ. Program. S. 338 - 346. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Fuerstenau, Moritz, Fink, Anna Maria, Schilhabel, Anke, Weiss, Jonathan, Robrecht, Sandra, Eckert, Robert, de la Serna, Javier, Crespo, Marta ORCID: 0000-0002-7732-7808, Coscia, Marta, Vitale, Candida, Boettcher, Sebastian, Weppner, Gesche, Ritgen, Matthias, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Brueggemann, Monika and Herling, Carmen D. (2021). B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 137 (16). S. 2267 - 2272. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Fink, Anna-Maria, Herling, Carmen, Maurer, Christian, Kutsch, Nadine, De La Serna, Javier, Coscia, Marta, Crespo, Marta, Bosch, Francesc ORCID: 0000-0001-9241-2886, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon P., Ritgen, Matthias, Schilhabel, Anke, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael J. and Eichhorst, Barbara (2018). B-cell acute lymphoblastic leukemia (BALL) in CLL patients treated with lenalidomide. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fuerstenau, Moritz, Giza, Adam, Stumpf, Thomas, Robrecht, Sandra, Maurer, Christian, Linde, Hartmut, Jacobasch, Lutz, Doerfel, Steffen, Aldaoud, Ali, von Tresckow, Julia, Koenigsmann, Michael, Gaska, Tobias, Kaiser, Ulrich, Harich, Hanns-Detlev, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Fink, Anna-Maria (2021). Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am. J. Hematol., 96 (12). S. E457 - 4. HOBOKEN: WILEY. ISSN 1096-8652

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Hallek, Michael and Theurich, Sebastian ORCID: 0000-0001-5706-8258 (2020). Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 34 (4). S. 1177 - 1182. LONDON: SPRINGERNATURE. ISSN 1476-5551

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Theurich, Sebastian (2018). Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Langerbeins, Petra, De Silva, Nisha, Fink, Anna Maria, Robrecht, Sandra, von Tresckow, Julia, Simon, Florian, Hohloch, Karin, Droogendijk, Jolanda, van der Klift, Marjolein, van der Spek, Ellen, Illmer, Thomas, Schoettker, Bjoern, Fischer, Kirsten, Wendtner, Clemens M., Tausch, Eugen, Stilgenbauer, Stephan, Niemann, Carsten U., Gregor, Michael, Kater, Arnon P., Hallek, Michael and Eichhorst, Barbara (2020). COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 34 (8). S. 2225 - 2230. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Furstenau, Moritz, Bahlo, Jasmin, Fink, Anna-Maria, Lange, Elisabeth, Dreger, Peter, Dreyling, Martin, Hess, Georg, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Boettcher, Sebastian, Hallek, Michael and Eichhorst, Barbara (2018). Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjorn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C., Lindstroem, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton and Kater, Arnon P. (2022). High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz ORCID: 0000-0002-6593-0140, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael and Cramer, Paula ORCID: 0000-0003-4046-9922 (2022). Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clin. Cancer Res., 28 (19). S. 4203 - 4212. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Goede, Valentin, Bahlo, Jasmin, Kutsch, Nadine, Fischer, Kirsten, Fink, Anna Maria, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Bergmann, Manuela A., Eichhorst, Barbara F. and Hallek, Michael (2016). Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goede, Valentin, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Fink, Anna-Maria, Stilgenbauer, Stephan, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens (2017). Cumulative Illness Rating Scale (CIRS) provides prognostic information beyond the International Prognostic Index for chronic lymphocytic leukemia (CLL-IPI): analysis of 3 randomized trials of the German CLL Study Group. Leuk. Lymphoma, 58. S. 96 - 99. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Goede, Valentin, Engelke, Anja, Fischer, Kirsten, Lopez Jimenez, Javier, Kuzmin, Alexej, Dyer, Martin J. S., Le Du, Katell, Liberati, Anna Marina, Schlag, Rudolf, Langerak, Anton W., Ritgen, Matthias, Stilgenbauer, Stephan, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael K., Fingerle-Rowson, Guenter and Hallek, Michael (2014). Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goede, Valentin, Fischer, Kirsten, Bosch, Francesc ORCID: 0000-0001-9241-2886, Follows, George, Frederiksen, Henrik ORCID: 0000-0001-8905-0220, Cuneo, Antonio, Ludwig, Heinz, Crompton, Noelle, Maurer, Joerg, Uguen, Marianne, Fingerle-Rowson, Gunter and Hallek, Michael (2015). Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goede, Valentin, Fischer, Kirsten, Busch, Raymonde, Engelke, Anja, Eichhorst, Barbara, Wendtner, Clemens M., Chagorova, Tatiana, de la Serna, Javier, Dilhuydy, Marie-Sarah, Illmer, Thomas, Opat, Stephen, Owen, Carolyn J., Samoylova, Olga, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Doehner, Hartmut, Langerak, Anton W., Ritgen, Matthias, Kneba, Michael, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael and Hallek, Michael (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 370 (12). S. 1101 - 1111. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Goede, Valentin, Fischer, Kirsten and Hallek, Michael (2014). Chemoimmunotherapy for Chronic Lymphocytic Leukemia REPLY. N. Engl. J. Med., 370 (24). S. 2348 - 2350. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Goede, Valentin, Fischer, Kirsten, Raymonde, Busch, Ulrich, Jaeger, Dilhuydy, Marie-Sarah, Wickham, Nicholas, De Guibert, Sophie, Fink, Anna Maria, Hagist, Susanne, Pflug, Natali, Bahlo, Jasmin, Kranz, Gabriele, Bieska, Gabriel, Humphrey, Kathryn, Bishop, Helen, Wenger, Michael and Hallek, Michael (2010). Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial. Blood, 116 (21). S. 597 - 598. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Hallek, Michael and Fischer, Kirsten (2016). Why this Trial Is Important to Us. Oncol. Res. Treat., 39 (1-2). S. 71 - 72. BASEL: KARGER. ISSN 2296-5262

Herling, Carmen D., Coombes, Kevin R., Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary B., Majewski, Tadeusz, Bondaruk, Jolanta E., Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A., Oakes, Christopher C., Ferrajoli, Alessandra, Keating, Michael J. and Abruzzo, Lynne V. (2019). Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol., 20 (11). S. 1576 - 1587. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Herling, Carmen D., Cymbalista, Florence, Gross-Ophoff-Mueller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael ORCID: 0000-0002-5277-4679, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Lepretre, Stephane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Doehner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Levy, Vincent (2020). Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 34 (8). S. 2038 - 2051. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Herling, Carmen Diana, Klaumuenzer, Marion, Rocha, Cristiano Krings, Altmueller, Janine, Thiele, Holger, Bahlo, Jasmin, Kluth, Sandra, Crispatzu, Giuliano, Herling, Marco, Schiller, Joanna, Engelke, Anja, Tausch, Eugen, Doehner, Hartmut, Fischer, Kirsten, Goede, Valentin, Nuernberg, Peter, Reinhardt, Hans Christian, Stilgenbauer, Stephan, Hallek, Michael and Kreuzer, Karl-Anton (2016). Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood, 128 (3). S. 395 - 405. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Hoechstetter, Manuela A., Busch, Raymonde, Eichhorst, Barbara, Buhler, Andreas, Winkler, Dirk, Bahlo, Jasmin, Robrecht, Sandra, Eckart, Michael J., Vehling-Kaiser, Ursula, Jacobs, Georg, Jaeger, Ulrich, Hurtz, Hans Juergen, Hopfinger, Georg, Hartmann, Frank, Fuss, Harald, Abenhardt, Wolfgang, Blau, Ilona, Freier, Werner, Mueller, Lothar, Goebeler, Maria, Wendtner, Clemens, Fischer, Kirsten, Herling, Carmen D., Starck, Michael, Bentz, Martin, Emmerich, Bertold, Doehner, Hartmut, Stilgenbauer, Stephan and Hallek, Michael (2020). Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia, 34 (4). S. 1038 - 1052. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Fuerstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael ORCID: 0000-0002-7425-4455, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 139 (9). S. 1318 - 1330. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Jaramillo, Sonia, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Doehner, Hartmut, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas and Stilgenbauer, Stephan (2020). Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group. Haematologica, 105 (11). S. 2598 - 2608. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Landau, Dan A., Bahlo, Jasmin, Robrecht, Sandra, Taylor-Weiner, Amaro N., Bloehdorn, Johannes, Scheffold, Annika, Mertens, Daniel ORCID: 0000-0003-0227-7188, Boettcher, Sebastian, Kneba, Michael, Jaeger, Ulrich, Zenz, Thorsten, Wenger, Michael K., Fingerle-Rowson, Guenter, Wendtner, Clemens, Fink, Anna-Maria, Wu, Catherine J., Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2019). Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia, 33 (9). S. 2183 - 2195. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Jenke, Petra, Eichhorst, Barbara, Busch, Raymonde, Anheier, Nadine, Duehrsen, Ulrich, Duerig, Jan, Dreyling, Martin H., Bergmann, Manuela, Goebeler, Maria Elisabeth, Hurts, Hans Juergen, Stauch, Martina Beate, Stilgenbauer, Stephan, Doehner, Hartmut, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin and Hallek, Michael (2011). Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. Blood, 118 (21). S. 1233 - 1235. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Julia, Von Tresckow, Carsten, Niemann, Kater, Arnon P., Bahlo, Jasmin, Farstenau, Moritz, Fink, Anna-Maria, Gregor, Michael, Thornton, Patrick, Tadmor, Tamar, Fischer, Kirsten, Ritgen, Matthias, Kreuzer, Karl A., Eldering, Eric, Stilgenbauer, Stephan, Van Oers, Marinus, Geisler, Christian, Hallek, Michael J. and Eichhorst, Barbara (2018). The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Julia, Von Tresckow, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Fuerstenau, Moritz, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl A., Ritgen, Matthias, Boettcher, Sebastian, Wendtner, Clemens Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael J. (2018). Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas ORCID: 0000-0003-3864-8315, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus ORCID: 0000-0001-7080-4643, Hallek, Michael ORCID: 0000-0002-7425-4455, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz and Rixecker, Torben Millard (2022). KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematol., 9 (2). S. E133 - 10. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Kater, Arnon P., Shanafelt, Tait, Fischer, Kirsten and Wierda, William (2012). Highlights of the 6th Young Investigators' Meeting on chronic lymphocytic leukemia. Leuk. Lymphoma, 53 (11). S. 2312 - 2314. LONDON: INFORMA HEALTHCARE. ISSN 1042-8194

Klaeger, Susan, Tausch, Eugen, Knisbacher, Binyamin A., Apffel, Annie, Clauser, Karl R., Williams, Corinne, Clish, Clary, Rassenti, Laura Z., Kipps, Thomas J., Fischer, Kirsten, Hallek, Michael, Gillette, Michael A., Neuberg, Donna S., Getz, Gad, Mani, Dr, Stilgenbauer, Stephan, Wu, Catherine J. and Carr, Steven A. (2022). Proteogenomic Analysis of SF3B1mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways. Blood, 140. S. 9838 - 9840. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Bahlo, Jasmin, Kluth, Sandra, Cramer, Paula, Fink, Anna-Maria, Fischer, Kirsten, Gross-Ophoff-Mueller, Carolin, Langerbeins, Petra, Maurer, Christian, von Tresckow, Julia, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Hallek, Michael, Eichhorst, Barbara and Goede, Valentin (2015). Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Boettcher, Sebastian, Bahlo, Jasmin, Kluth, Sandra, Ritgen, Matthias, Fink, Anna Maria, Stodden, Irene, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Doehner, Hartmut, Stilgenbauer, Stephan, Kneba, Michael, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2014). Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Gunter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Boettcher, Sebastian (2016). Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J. Clin. Oncol., 34 (31). S. 3758 - 3775. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Franklin, Jeremy, Zhang, Can, Maurer, Christian, De Silva, Nisha, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria, Hallek, Michael and Eichhorst, Barbara (2020). Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere, 4 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael, Soekler, Martin, Schlag, Rudolf, Fink, Anna-Maria, Vehling-Kaiser, Ursula, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Eichhorst, Barbara (2017). Health related quality of life (HRQOL) of patients treated with FCR vs BR within the CLL10 trial. Leuk. Lymphoma, 58. S. 109 - 111. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Busch, Raymonde, Bahlo, Jasmin, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg ORCID: 0000-0002-8321-1342, Hess, Georg, von Gruenhagen, Ulrich, Wendtner, Clemens-Martin, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2017). FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 58 (2). S. 399 - 408. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Fink, Anna Maria, Federhen, Anno, Giza, Adam, Robrecht, Sandra, Stumpf, Janina, Stoltefuss, Andrea, Vehling-Kaiser, Ursula, Koenigsmann, Michael, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Illmer, Thomas, Schlag, Rudolf, Doerfel, Steffen, Gaska, Tobias, Kiehl, Michael G., Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2022). Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry. Blood, 140. S. 9879 - 9882. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kutsch, Nadine, Fink, Anna Maria and Fischer, Kirsten (2022). Management of front line chronic lymphocytic leukemia. Am. J. Hematol., 97. S. S3 - 8. HOBOKEN: WILEY. ISSN 1096-8652

Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schueler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Mueller-Hagen, Sigrun, Heinisch, Karin, Boettcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens-Martin (2023). Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk. Lymphoma, 64 (2). S. 478 - 483. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Pallasch, Christian, Decker, Thomas ORCID: 0000-0003-3814-8775, Hebart, Holger, Chow, Kai Uwe, Graeven, Ullrich, Kisro, Jens, Kroeber, Alexander, Tausch, Eugen, Fischer, Kirsten, Fink, Anna-Maria, Wendtner, Clemens-Martin, Ritgen, Matthias, Stilgenbauer, Stephan, Zhang, Danjie, Li, Biao, Jurgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael ORCID: 0000-0002-7425-4455 and Eichhorst, Barbara (2022). Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere, 6 (6). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Kutsch, Nadine, Pallasch, Christian, Tausch, Eugen, Boehme, Volkmar, Ritgen, Matthias, Liersch, Ruediger, Wacker, Alexander, Jacobs, Georg, Trappe, Ralf Ulrich ORCID: 0000-0001-7565-7160, Dreger, Peter, Fischer, Kirsten, Fink, Anna-Maria, Stilgenbauer, Stephan, Zhai, Shuyan, Li, Biao, Jurgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael ORCID: 0000-0002-7425-4455 and Eichhorst, Barbara F. (2022). Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere, 6 (4). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Landau, Dan A., Tausch, Eugen, Boettcher, Sebastian, Stewart, Chip, Bozic, Ivana, Leischner, Iganty, Rosebrock, Daniel, Taylor-Weiner, Amaro, Mertens, Daniel, Sougnez, Carrie, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Kluth, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric, Dohner, Hartmut ORCID: 0000-0003-2116-5536, Hallek, Michael, Neuberg, Donna S., Nowak, Martin, Getz, Gad, Stilgenbauer, Stephan and Wu, Catherine J. (2015). Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Bottcher, Sebastian, Bahlo, Jasmin, Stewart, Chip, Edelmann, Jennifer, Kluth, Sandra, Mertens, Daniel, Kneba, Michael, Kless, Sabrina, Sougnez, Carrie, Fischer, Kirsten, Ritgen, Matthias, Gabriel, Stacey, Lander, Eric, Dohner, Hartmut ORCID: 0000-0003-2116-5536, Hallek, Michael, Getz, Gad, Neuberg, Donna, Stilgenbauer, Stephan and Wu, Catherine J. (2014). Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno) Therapy: Results from the CLL8 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Stewart, Chip, Reiter, Johannes G. ORCID: 0000-0002-0170-7353, Bahlo, Jasmin, Kluth, Sandra, Bozic, Ivana ORCID: 0000-0003-2761-825X, Lawrence, Mike, Boettcher, Sebastian, Carter, Scott L., Cibulskis, Kristian, Mertens, Daniel ORCID: 0000-0003-0227-7188, Sougnez, Carrie L., Rosenberg, Mara ORCID: 0000-0001-6400-3161, Hess, Julian M., Edelmann, Jennifer, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Fink, Anna, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric S., Nowak, Martin A., Doehner, Hartmut, Hallek, Michael, Neuberg, Donna, Getz, Gad, Stilgenbauer, Stephan and Wu, Catherine J. (2015). Mutations driving CLL and their evolution in progression and relapse. Nature, 526 (7574). S. 525 - 542. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-4687

Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trneny, Marek, Mulligan, Stephen P., Mey, Ulrich J. M., Trunzer, Kerstin, Fingerle-Rowson, Guenter, Humphrey, Kathryn, Stilgenbauer, Stephan, Boettcher, Sebastian, Brueggemann, Monika, Hallek, Michael, Kneba, Michael and van Dongen, Jacques J. M. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 133 (5). S. 494 - 498. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna Maria, Pflug, Natali, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Preliminary safety results of a placebo-controlled Phase III study of ibrutinib in treatment-nayve early stage CLL patients with risk of disease progression. Leuk. Lymphoma, 56. S. 20 - 22. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Reiser, Marcel, Wendtner, Clemens, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2017). Serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) in early stage patients with CLL treated with ibrutinib or placebo: safety results of the ongoing randomized CLL12 phase III-trial. Leuk. Lymphoma, 58. S. 161 - 163. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Pflug, Natali, Fischer, Kirsten, Stilgenbauer, Stephan, Kreuzer, Karl Anton, Wendtner, Clemens-Martin, Eichhorst, Barbara and Hallek, Michael (2015). The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol., 11 (13). S. 1895 - 1904. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Gerwin, Henrik, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael J., Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens Martin, Reiser, Marcel, Stauch, Martina, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2020). Ibrutinib versus placebo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Leuk. Lymphoma, 61. S. 18 - 21. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Busch, Raymonde, Anheier, Nadine, Duerig, Jan, Bergmann, Manuela, Goebeler, Maria-Elisabeth, Hurtz, Hans-Juergen, Stauch, Martina B., Stilgenbauer, Stephan, Doehner, Hartmut, Fink, Anna-Maria, Cramer, Paula, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael and Eichhorst, Barbara (2014). Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am. J. Hematol., 89 (12). S. E239 - 5. HOBOKEN: WILEY. ISSN 1096-8652

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood, 139 (2). S. 177 - 188. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Maurer, Christian, Pflug, Natali, Bahlo, Jasmin, Kluth, Sandra, Rhein, Christina, Cramer, Paula, Gross-Ophoff, Carolin, Langerbeins, Petra, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Fischer, Norbert, Tausch, Eugen, Stilgenbauer, Stephan, Boettcher, Sebastian, Doehner, Hartmut, Kneba, Michael, Dreyling, Martin, Binder, Mascha ORCID: 0000-0003-0663-3004, Hallek, Michael, Wendtner, Clemens-Martin, Bergmann, Manuela and Fischer, Kirsten (2016). Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur. J. Haematol., 97 (3). S. 253 - 261. HOBOKEN: WILEY. ISSN 1600-0609

Mellinghoff, Sibylle C., Mayer, Leonie, Robrecht, Sandra, Weskamm, Leonie M., Dahlke, Christine ORCID: 0000-0002-2056-9195, Gruell, Henning, Schlotz, Maike, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Schloesser, Hans A., Thelen, Martin ORCID: 0000-0002-2785-9726, Fink, AnnaMaria, Fischer, Kirsten, Klein, Florian ORCID: 0000-0003-1376-1792, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael and Langerbeins, Petra (2022). SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia. Haematologica, 107 (10). S. 2480 - 2485. PAVIA: FERRATA STORTI FOUNDATION. ISSN 1592-8721

Mellinghoff, Sibylle C., Robrecht, Sandra, Mayer, Leonie ORCID: 0000-0001-7102-4358, Weskamm, Leonie M., Dahlke, Christine, Gruell, Henning, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Schloesser, Hans A., Thelen, Martin ORCID: 0000-0002-2785-9726, Fink, Anna-Maria, Fischer, Kirsten, Klein, Florian, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael and Langerbeins, Petra (2022). SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia, 36 (2). S. 562 - 566. LONDON: SPRINGERNATURE. ISSN 1476-5551

Mueller, Dirk, Fischer, Kirsten, Kaiser, Peter, Eichhorst, Barbara, Walshe, Ronald, Reiser, Marcel, Kellermann, Lenka, Borsi, Lisa, Civello, Daniele, Mensch, Alexander, Bahlo, Jasmin, Hallek, Michael, Stock, Stephanie and Fingerle-Rowson, Guenter (2016). Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk. Lymphoma, 57 (5). S. 1130 - 1140. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Pan, Heng, Renaud, Loic ORCID: 0000-0001-7213-9464, Chaligne, Ronan, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Tausch, Eugen, Mertens, Daniel ORCID: 0000-0003-0227-7188, Fink, Anna Maria ORCID: 0000-0002-7669-7890, Fischer, Kirsten, Zhang, Chao, Betel, Doron ORCID: 0000-0002-8006-7752, Gnirkell, Andreas, Imielinski, Marcin, Moreaux, Jerome, Hallek, Michael, Meissner, Alexander, Stilgenbauer, Stephan, Wu, Catherine J., Elemento, Olivier and Landau, Dan A. (2021). Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discov., 11 (9). S. 2266 - 2282. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 2159-8290

Pflug, Natali, Bahlo, Jasmin, Shanafelt, Tait D., Eichhorst, Barbara F., Bergmann, Manuela A., Elter, Thomas, Bauer, Kathrin, Malchau, Gebhart, Rabe, Kari G., Stilgenbauer, Stephan, Doehner, Hartmut, Jaeger, Ulrich, Eckart, Michael J., Hopfinger, Georg, Busch, Raymonde, Fink, Anna-Maria, Wendtner, Clemens-Martin, Fischer, Kirsten, Kay, Neil E. and Hallek, Michael (2014). Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 124 (1). S. 49 - 63. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Pflug, Natali, Chakupurakal, Geothy, Fink, Anna-Maria, Robrecht, Sandra, Herling, Marco, Cramer, Paula, Holtick, Udo, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Schetelig, Johannes, Fischer, Kirsten, Ritgen, Matthias, Scheid, Christof, Eichhorst, Barbara, Dreger, Peter, Hallek, Michael and von Bergwelt-Baildon, Michael (2021). Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. Hemasphere, 5 (12). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Pflug, Natali, Kluth, Sandra, Vehreschild, Joerg J., Bahlo, Jasmin, Tacke, Daniela, Biehl, Lena, Eichhorst, Barbara, Fischer, Kirsten, Cramer, Paula, Fink, Anna-Maria, von Bergwelt-Baildon, Michael, Stilgenbauer, Stephan, Hallek, Michael, Cornely, Oliver A. and Vehreschild, Maria J. G. T. (2016). Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology, 5 (6). PHILADELPHIA: TAYLOR & FRANCIS INC. ISSN 2162-402X

Rusyn, Lisa, Reinartz, Sebastian, Nikiforov, Anastasia, Mikhael, Nelly, vom Stein, Alexander, Kohlhas, Viktoria, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Stilgenbauer, Stephan, Lohneis, Philipp, Buettner, Reinhard, Robrecht, Sandra, Fischer, Kirsten, Pallasch, Christian, Hallek, Michael ORCID: 0000-0002-7425-4455 and Seeger-Nukpezah, Tamina (2022). The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. Leukemia, 36 (7). S. 1794 - 1806. LONDON: SPRINGERNATURE. ISSN 1476-5551

Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara and Hallek, Michael (2019). Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials. Anticancer Res., 39 (5). S. 2591 - 2599. ATHENS: INT INST ANTICANCER RESEARCH. ISSN 1791-7530

Samineni, Divya, Gibiansky, Leonid, Wang, Bei, Vadhavkar, Shweta, Rajwanshi, Richa, Tandon, Maneesh, Sinha, Arijit, Al-Sawaf, Othman, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455, Salem, Ahmed Hamed, Li, Chunze and Miles, Dale (2022). Pharmacokinetics and Exposure-Response Analysis of Venetoclax plus Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Adv. Ther., 39 (8). S. 3635 - 3654. NEW YORK: SPRINGER. ISSN 1865-8652

Schilhabel, Anke, Walter, Peter Jonas, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Kohlscheen, Saskia, Szczepanowski, Monika ORCID: 0000-0001-5482-8880, Laqua, Anna, Fischer, Kirsten, Eichhorst, Barbara, Boettcher, Sebastian, Schneider, Christof, Tausch, Eugen, Brueggemann, Monika, Kneba, Michael, Hallek, Michael ORCID: 0000-0002-7425-4455 and Ritgen, Matthias (2022). CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers, 14 (19). BASEL: MDPI. ISSN 2072-6694

Segura, Sonia Jaramillo, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Doehner, Hartmut, Brandell, Richard Rosenquist, Ghia, Paolo, Stamatopoulos, Kostas and Stilgenbauer, Stephan (2020). Prognostic impact of common chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Leuk. Lymphoma, 61. S. 135 - 137. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Shanafelt, Tait D., Parikh, Sameer A., Noseworthy, Peter A., Goede, Valentin, Chaffee, Kari G., Bahlo, Jasmin, Call, Timothy G., Schwager, Susan M., Ding, Wei, Eichhorst, Barbara, Fischer, Kirsten, Leis, Jose F., Chanan-Khan, Asher Alban, Hallek, Michael, Slager, Susan L. and Kay, Neil E. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma, 58 (7). S. 1630 - 1640. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Simon, Florian, Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Fuerstenau, Moritz, Goede, Valentin, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455 and Al-Sawaf, Othman (2022). Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leuk. Lymphoma, 63 (14). S. 3299 - 3307. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Stilgenbauer, Stephan, Busch, Raymonde, Schnaiter, Andrea, Paschka, Peter, Rossi, Marianna, Doehner, Konstanze, Zenz, Thorsten, Buehler, Andreas, Winkler, Dirk, Edelmann, Jennifer, Mertens, Daniel, Bullinger, Lars, Kless, Sabrina, Mack, Silja, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Jaeger, Ulrich, Lichter, Peter, Patten, Nancy, Wenger, Michael K., Mendila, Myriam, Fingerle-Rowson, Gunter, Cazzola, Mario, Wendtner, Clemens, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael and Doehner, Hartmut (2012). Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Stilgenbauer, Stephan, Schnaiter, Andrea, Paschka, Peter, Zenz, Thorsten, Rossi, Marianna ORCID: 0000-0003-1661-1511, Doehner, Konstanze, Buehler, Andreas, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Winkler, Dirk, Tausch, Eugen, Hoth, Patrick, Edelmann, Jennifer, Mertens, Daniel ORCID: 0000-0003-0227-7188, Bullinger, Lars, Bergmann, Manuela, Kless, Sabrina, Mack, Silja, Jaeger, Ulrich, Patten, Nancy, Wu, Lin, Wenger, Michael K., Fingerle-Rowson, Guenter, Lichter, Peter, Cazzola, Mario, Wendtner, Clemens M., Fink, Anna M., Fischer, Kirsten, Busch, Raymonde, Hallek, Michael and Doehner, Hartmut (2014). Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood, 123 (21). S. 3247 - 3255. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lura, Michele Porro, Kneba, Michael, Doehner, Hartmut, Fischer, Kirsten, Hallek, Michael and Stilgenbauer, Stephan (2020). Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 135 (26). S. 2402 - 2413. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tiao, Grace, Improgo, M. Reina, Tausch, Eugen, Fernandes, Stacey M., Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Kiezun, Adam, Getz, Gad and Brown, Jennifer R. (2017). Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood, 130 (22). S. 2443 - 2445. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Weisser, Martin, Yeh, Ru-Fang, Duchateau-Nguyen, Guillemette, Palermo, Giuseppe, Shi, Xiaoyan, Stinson, Susanna Y., Yu, Nancy, Dufour, Annika, Robak, Tadeusz, Salogub, Galina N., Dmoszynska, Anna, Solal-Celigny, Philippe, Warzocha, Krzysztof ORCID: 0000-0002-2396-3905, Loscertales, Javier, Catalano, John, Larratt, Loree, Rossiev, Viktor A., Bence-Bruckler, Isabelle, Geisler, Christian H., Montillo, Marco, Fischer, Kirsten, Fink, Anna-Maria, Hallek, Michael, Bloehdorn, Johannes, Busch, Raymonde, Benner, Axel, Doehner, Hartmut, Valente, Nancy, Wenger, Michael K., Stilgenbauer, Stephan and Dornan, David (2014). PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood, 124 (3). S. 420 - 426. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Wolf, Christine, Garding, Angela, Filarsky, Katharina, Bahlo, Jasmin, Robrecht, Sandra, Becker, Natalia, Zucknick, Manuela ORCID: 0000-0003-1317-7422, Rouhi, Arefeh, Weigel, Anja, Claus, Rainer ORCID: 0000-0003-2617-8766, Weichenhan, Dieter, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael, Kuchenbauer, Florian, Plass, Christoph, Doehner, Hartmut, Stilgenbauer, Stephan, Lichter, Peter and Mertens, Daniel ORCID: 0000-0003-0227-7188 (2018). NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int. J. Cancer, 142 (2). S. 322 - 334. HOBOKEN: WILEY. ISSN 1097-0215

Yosifov, Deyan Yordanov ORCID: 0000-0002-5473-4398, Idler, Irina, Bhattacharya, Nupur, Reichenzeller, Michaela, Close, Viola, Ezerina, Daria ORCID: 0000-0002-3104-7093, Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Kugler, Sabrina, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Eichhorst, Barbara, Fischer, Kirsten, Weigel, Anja, Busch, Hauke ORCID: 0000-0003-4763-4521, Lichter, Peter, Doehner, Hartmut, Dick, Tobias P., Stilgenbauer, Stephan and Mertens, Daniel ORCID: 0000-0003-0227-7188 (2020). Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia, 34 (1). S. 115 - 128. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Klaproth, Holger, Tausch, Eugen, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2015). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Bottcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael (2019). CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 33 (5). S. 1161 - 1173. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

von Tresckow, Julia ORCID: 0000-0001-5873-4603, Cramer, Paula ORCID: 0000-0003-4046-9922, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Fuerstenau, Moritz, Illmer, Thomas, Klaproth, Holger, Tausch, Eugen, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael ORCID: 0000-0002-7425-4455 (2022). Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 36 (8). S. 2125 - 2129. LONDON: SPRINGERNATURE. ISSN 1476-5551